Deals tracker: iRhythm to acquire VitalConnect
iRhythm is set to acquire VitalConnect, adding a transaction catalyst to the company’s growth story. The available data show strong revenue growth but continuing losses, leaving deal execution and the path to profitability as the key setup for IRTC.
STOCK PHOTO · TIMA MIROSHNICHENKOThe story
iRhythm is set to acquire VitalConnect, according to the Deals Tracker item from Modern Healthcare.
The transaction adds a strategic catalyst to IRTC, which reported FY2025 revenue of $747.1M, up 26.2% YoY. The company also recorded a 70.6% gross margin, but remained unprofitable with a -6.0% net margin and $-1.39 diluted EPS.
That combination creates a clear bull case around broader connected-cardiac-monitoring scale and a bear case around integration, funding, and dilution risk.
The next signals are the definitive transaction terms, financing structure, regulatory or closing conditions, and any guidance for revenue, margins, or cash use after the deal.
Our read · Sat, Aug 8
The VitalConnect acquisition adds strategic upside but leaves deal terms, funding and profitability risk unresolved for IRTC.
Why. The acquisition could expand IRTC’s connected-care platform. The existing financial profile is mixed: FY2025 revenue grew 26.2% YoY to $747.1M with a 70.6% gross margin, while net margin was -6.0% and diluted EPS was $-1.39.
Both cases
What could change this view: A costly or equity-funded transaction, integration problems, or no improvement in the company’s losses would undermine the strategic case.
Who reported it · 1
Keep reading
Latest on the Wire
Nvidia tumbles as US tech stocks enter bear market on AI spending fearsTrump threatens overseas AI data-centre ban for US firmsBitcoin drops below $59,000 as cash rush revives summer-low testGreer says US chip curbs will close China export-control loopholesBlackRock bitcoin ETF posts $541.1 million outflow as tech sell-off spreadsContinue on the Wire →Latest on the Wire
Poland says Russian missiles and drone crashed during Ukraine assaultAnthropic debut fails to halt technology-led slide in US stocksUS MATCH Act puts ASML at center of China chip export disputeBeijing plans to bar young red-chip firms from overseas listingsContinue on the Wire →Top this week
Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangAnthropic IPO could become the largest in US history on ThursdayAbout this report
Reported by modernhealthcare.com, . Who answers for this
The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →